Losmapimod
As of the edition of 20 October 2026, Losmapimod is a small molecule: stopped in 2024; acts on MAPK11 and MAPK14.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 26, 5 stopped early
- Disease areas
- Heart and blood vessels; Bones, joints and muscles; Lungs and airways; Nervous system; Inherited and neonatal; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Losmapimod.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 2 | 16 | 13 | 0 | 3 |
| Phase 3 | 3 | 1 | 0 | 2 |
| All trials | 26 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2005 to now |
| Fulcrum Therapeutics | Lead sponsor of trials | 2019 to now |